Impacto da COVID-19 na Cirurgia de Transplantação Corneana: Primeiro EuCornea Educational Webinar by Moura-Coelho, N et al.
  Volume 45 - N1 - Janeiro-Março   |   45
KEYWORDS: Eye Banks; Corneal Transplantation; first EuCornea Educational Webinar; CO-
VID-19; SARS-CoV-2
Impact of COVID-19 on Corneal 
Transplantation: 
First EuCornea Education Webinar
Impacto da COVID-19 na Cirurgia de 
Transplantação Corneana: Primeiro 
EuCornea Educational Webinar 
Nuno Moura-Coelho1,2,3,4, João Paulo Cunha3,5, José Güell1,6
1 Cornea and Refractive Surgery Department, Instituto de Microcirugía Ocular (IMO) Barcelona, Barcelona, Spain
2 NOVA Medical School | Faculdade de Ciências Médicas – Universidade Nova de Lisboa (NMS | FCM – UNL), Lisbon, Portugal
3 Ophthalmology, Hospital CUF Cascais, Cascais, Portugal
4 Ophthalmology, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal
5 Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa (ESTeSL, IPL), Lisbon, Portugal




© Author(s) or their employer(s) and Oftalmologia 2021. Re-use permitted under CC BY-NC. No commercial re-use. 
© Autor(es) ou seu(s) empregador(es) e Oftalmologia 2021. Reutilização permitida de acordo com CC BY-NC. Nenhuma reutilização comercial.
The ophthalmic scientific community has been put to 
test throughout the COVID-19 disease pandemic, and the 
several, successful virtual scientific meetings and webinars 
have demonstrated the great impact of social media in scien-
tific communication.1 In 11th March 2020, the World Health 
Organization declared the COVID-19 outbreak a pandemic. 
One year later, the ophthalmologist community “e-gathe-
red” to attend the first EuCornea Educational Webinar in 11th 
March 2021, which addressed the subject of corneal grafting 
and COVID-19.
During the pandemic, four main issues regarding risk 
management have been recognized: 1) the risk to sufficien-
cy and sustainability of donor corneas, 2) the risk regarding 
viral status of the donor tissue, 3) the risk to eye bank and 
ophthalmology department staff, and 4) the risk to corneal 
graft recipients. Rethinking eye surgery and ocular tissue 
processing and preservation strategies was essential from 
the outset, as the ocular surface harbours proteins which 
allow SARS-CoV-2 virus entry into ocular surface cells, and 
as the virus RNA has been detected in conjunctival swabs 
of patients with COVID-19. In addition, a spectrum of ocu-
lar manifestations has been described in patients with CO-
VID-19, although the incidence of conjunctivitis and other 
ocular complications appears to be low.2
In response to the COVID-19 pandemic, Ophthalmology 
departments and Eye Banks worldwide were placed in lo-
ckdown or reorganized into “COVID-19 units” in the early 
phase of the pandemic, and since then have resumed their 
activity at variable rates. Early in the pandemic, eye banks 
adapted quickly, and reduced procurement led to an excess 
of available tissue, with the problem of limited tissue shelf 
time. In Europe, the number of procurements decreased 
by 38%-68% between March-May 2020, compared with the 
mean of the two previous years.3 Later, with the progressive 
adaptation of both eye banks and cornea departments, incre-
ased pressure has been imposed on eye banks due to increa-
sed deferrals. Importantly, during the webinar it was highli-
ghted that these changes were felt more strongly in smaller 
eye banks compared with higher-volume eye banks. Several 
strategies have been proposed to address these issues, inclu-
ding storage of dehydrated corneas (which may last up to 6 
months in storage) particularly for anterior lamellar kerato-
plasty4,5; the use of hemi- and quarter-DMEK grafts5; and the 
use of one donor cornea for multiple recipients.6
Additional complexities in transplantation during the 
pandemic include questions regarding donor and recipient 
screening. It is still not definitive whether donor corneal tis-
sues harbour the SARS-CoV-2 RNA, with conflicting findin-
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gs in the literature,7-9 including findings of both RNA and 
the envelope and spike proteins in one study,9 and positive 
findings in asymptomatic donors in another study.10 From 
588 donors from the Veneto Eye Bank Foundation without 
medical evidence nor epidemiological links to COVID-19 ca-
ses, only three cases (0.5%) tested positive for SARS-CoV-2 
in nasopharyngeal rt-PCR samples, of which two corneal 
specimens yielded SARS-CoV-2 RNA.10 During the webinar, 
speakers pointed out that positive genomic tests may not 
relate to viral replicability, as cases with detectable SARS-
-CoV-2 RNA in corneal tissue have low small genomic RNA 
expression, which suggests low or no viral replicability; and 
Dr Thuret mentioned that no bilateral positive cases were 
found, although unilateral infection may be possible. Be-
sides, Dr Thuret found high inter-individual variability of 
ACE-2 and TMPRSS2 expression, meaning donors with po-
sitive nasopharyngeal PCR may not have corneal positivity. 
Despite these controversies, it is generally considered that 
the overall risk of transmission of SARS-CoV-2 through ke-
ratoplasty may be low, but that further research is warranted 
to assess the rate of SARS-CoV-2 transmission. Dr Dickmann 
pointed out that this is supported by the fact that there is no 
known transmission of other respiratory viruses in corneal 
grafts. Even so, until further data is available, most inter-
national guidelines avoid donor tissues from patients with 
COVID-19 disease. Current EEBA guidelines state that pa-
tients with active COVID-19 disease at time of death must be 
excluded from corneal donation, but that people with a posi-
tive PCR >14 days before death may be eligible 2 weeks after 
complete recovery and symptom-free at the time of death.11 
Post-mortem nasopharyngeal PCR testing is therefore criti-
cally important,9,12 particularly in individuals with unknown 
status prior to death.11 According to the webinar speakers, 
further testing (including Western blot testing) likely has no 
added value to the validation of PCR results.
Regarding donor ocular tissue preparation, although 
concerns have arisen for potential ocular infectivity and in-
fection of collection team staff,13 with adequate protective 
measures this risk may be very low.8 Since it appears that 
SARS-CoV-2 viral replication and its lytic activity restricts to 
epithelia, removal of all conjunctival tissue and corneal epi-
thelial removal with povidone-iodine (PVI) is a crucial step 
in donor preparation.9 Although further evidence is required 
to demonstrate its efficacy on SARS-CoV-2 in corneal tissues, 
coronaviruses in inanimate surfaces appear to be rapidly 
inactivated following PVI exposure; the European Center for 
Disease Control considers PVI exposure to be validated for 
enveloped virus, and the current EBAA Medical Standard 
requires double exposure to PVI at the ocular surface before 
tissue recovery. However, eye banks and ophthalmologists 
must remain aware that PVI does not accomplish complete 
sterilization, nor does it eliminate the possibility of viral re-
tention within ocular structures.14 
It is recommended that patients undergo RT-PCR before 
keratoplasty and that PCR-positive patients are postponed, 
unless the emergent cases, in which all surgical staff should 
wear full protective equipment.13 Dr Ponzin suggested that 
endothelial keratoplasty may be a safer procedure compared 
with penetrating keratoplasty, since the corneal endothelial 
layer lacks ACE-2 and TMPRSS2. The postoperative follow-
-up must take into account the possibility of the patient being 
infected with SARS-CoV-2, which may increase susceptibili-
ty for immune rejection episodes, possibly to viral induction 
of a proinflammatory state.15 Finally, Dr Dickmann stated 
that COVID-19 vaccination is safe in corneal transplant pa-
tients. However, it may be advisable to increase immuno-
suppressive treatment in patients with corneal allografts 
undergoing COVID-19 vaccination, particularly in patients 
at increased risk of rejection such as patients with corneal 
regrafts; webinar speakers mentioned two cases of rejection 
episodes shortly following vaccination. Dr Dickmann sug-
gested increasing topical steroids to 4 times daily 2 days be-
fore vaccination and for a period of 2 weeks, and highlighted 
the importance of keratoplasty patients to watch out for po-
tential signs of graft rejection under the “RSVP” acronym for 
redness, sensitivity to light, vision blurring, and pain.
In conclusion, the first EuCornea Educational Webinar we-
aved sound considerations into corneal transplantation and 
eye banking during the COVID-19 pandemic. Key messages 
are that transplant activity during a pandemic should be 
fluid and tailored, with careful donor and recipient selec-
tion. International existing networks including EuCornea 
and the EEBA facilitate communication and foster coopera-
tion to minimize the influence of the pandemic on donation 
and corneal transplantation activity. Prompt adaptation by 
eye banks and cornea departments allowed normalization 
of corneal grafting activity throughout Europe; that is, the 
“corneal transplantation chain” is rapidly adaptive, albeit at 
variable rates throughout Europe. With the appropriate me-
asures for donor collection and preparation, and with careful 
perioperative protective measures, healthcare professionals 
and keratoplasty recipients likely have a low infectivity risk. 
Future challenges ahead will include the management of 
corneal patients undergoing COVID-19 vaccination, as well 
as further identification of potential donors among those 
with previous history of COVID-19 disease. 
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